TrialHuman vaccines & immunotherapeutics2025
Efficacy, immunogenicity, and safety of heterologous boosting with a novel chimera Chinese mRNA (RQ3013) SARS-CoV-2 vaccine: A randomized, double-blind, active-controlled trial.
Xiao-Qiang Liu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.